Skip to main content
. 2020 Dec 29;11(52):4836–4844. doi: 10.18632/oncotarget.27848

Figure 3. Timeline of the case and changes in lymphocyte count during treatment with temozolomide.

Figure 3

(A) The timeline of the case report. (B) Demonstrates the evidence of an inflammatory tumor status at progression after treatment with ICI, to the left of the panel immunohistochemistry staining demonstrates PD-L1 expression > 30% and to the right RNA sequencing using Tempus xT identified tumor cell infiltration with immune cells composing 27% of the tumor infiltrate with predominance of T-cell infiltration constituting 44% of the infiltrate.